Table 1 Study characteristics of the included studies
Study | Species (sex, weight) | Model | N = experimental/control group | Ischemia duration | Time of administration | Control group | Experimental group (drug/daily dosage/frequency, approach, duration) | Outcomes |
|---|---|---|---|---|---|---|---|---|
Yang LX 2016(China) [21] | Rat/SD (M, 270–320 g) | MCAO/R | 20/22 | 2 h | 1 h before MCAO | NS | Ginsenoside, 10 mg/kg, qd, i.p., 7 d | Longa |
Xie CL 2015(China) [22] | Rat/SD (M, 250–300 g) | MCAO/R | 12/12 | 2 h | 3 d before MCAO | NS | Ginsenoside, 40 mg/kg, qd, i.p., 14 d | Longa |
Lin M 2015 (China) [23] | Rat/SD (M, 280–320 g) | MCAO/R | 10/10 | 2 h | 2 h after I/R | NS | Ginsenoside, 60 mg/kg, bid, i.v., 3 d | Longa |
Zhou Y 2014 (China) [24] | Rat/SD (M, 230–280 g) | MCAO/R | 12/12 | 2 h | 3 d before MCAO | NS | Ginsenoside, 20 mg/kg, bid, i.p., 14 d | Longa |
Wang C 2023 (China) [25] | Rat/SD (M, 140–160 g) | MCAO/R | 12/12 | 1.5 h | 0 h after MCAO | NS | Scutellarin, 12 mg/kg, tid, i.v., 12 h | Longa |
Xu S 2017 (China) [26] | Rat/Wistar (M, 180–220 g) | MCAO/R | 10/10 | 1 h | NI | NS | Salvianolic acid, 12 mg/kg,/, i.p., 3 d | Longa |
Altinay S 2017(Turkey) [27] | Rat/Wistar (female, 400–500 g) | BCCAO/R | 8/8 | 0.5 h | NI | NS | Curcumin, 300 mg/kg, qd, i.p., 3 d | Longa |
Li L 2023 (China) [28] | Rat/SD (M, 280–300 g) | MCAO/R | 16/16 | 1.5 h | 0 h after I/R | NI | Quercetin, 50 mg/kg, qd, ip, 3 d | Longa |
Wu WN 2011 (China) [29] | Rat/SD (M, 220–250 g) | MCAO/R | 4/4 | 2 h | 1 h after MACO | distilled water | Sinomenine, 30 mg/kg, qd, i.p., 7 d | Longa |
Yang S 2019 (China) [30] | Rat/SD (M, 290–310 g) | MCAO/R | 6/6 | 1.5 h | 24 h after I/R | NI | Baicalein, 200 mg/kg, qd, i.g., 7 d | Longa, mNSS |
Tang H 2021 (China) [31] | Rat/SD (M, 200–250 g) | MCAO/R | 10/10 | 1.5 h | 2 h after MCAO | 150 ul saline and 20% DMSO | Paeoniflorin, 10 mg/kg, bid, i.p., 14 d | mNSS |
Shi YH 2021 (China) [32] | Rat/SD (M, 250–280 g) | MCAO/R | 12/12 | 2 h | 3 d before MCAO | NS | Astragaloside IV, 20 mg/kg, qd, i.p., 7 d | mNSS |
Li L 2021 (China) [33] | Rat/SD (M, 280–300 g) | MCAO/R | 10/10 | 1.5 h | NI | NS | Astragaloside IV, 40 mg/kg, qd, i.p., 14 d | mNSS |
Wang N 2014 (China) [34] | Rat/SD (M, 250–270 g) | MCAO/R | 10/10 | 2 h | 1 h after MCAO | NI | Puerarin, 23.59 mg/kg,/, i.g., 7 d | mNSS, IV |
Wu M 2014 (China) [35] | Rat/Wistar (M, 280–320 g) | MCAO/R | 18/18 | 2 h | 24 h after MCAO | NS | Puerarin, 100 mg/kg, qd, i.p., 14 d | mNSS |
Wu S 2021 (China) [36] | Rat/SD (M, 250–280 g) | MCAO/R | 6/6 | 1.5 h | 0.5 h before MCAO | NI | Curcumin, 300 mg/kg,/, i.p., 7 d | mNSS |
Wang Y 2019 (China) [37] | Mice/C57BL/6 J (M, 26–28 g) | MCAO/R | 5/5 | 0.5 h | NI | PBS | Curcumin, 25 mg/kg,/, i.v., 3 d | mNSS |
Cui Q 2021 (China) [38] | Rat/SD (M, 230–260 g) | MCAO/R | 6/6 | 2 h | NI | NS | Hydroxysafflor yellow A, 10 mg/kg, qd, i.v., 3 d | mNSS |
Yan M 2023 (China) [39] | Rat/SD (M, 250–280 g) | MCAO/R | 6/6 | 2 h | 6 h after I/R | PBS | Salvianolic acid, 20 mg/kg, qd, i.g., 14 d | mNSS |
Yao RQ 2012 (China) [40] | Rat/SD (M, 250–270 g) | MCAO/R | 12/12 | 1.5 h | 3 h after MCAO | distilled water | Quercetin, 20 mg/kg, qd, i.g., 28 d | mNSS |
Gao XQ 2010 (China) [41] | Rat/Wistar (M, 250–300 g) | MCAO/R | 4/4 | 2 h | 0 h after I/R | isotonic saline | Ginsenoside, 40 mg/kg,/, i.p., 10 d | mNSS |
Zhu J 2012 (China) [42] | Rat/SD (M, 220–250 g) | MCAO/R | 12/12 | 2 h | 7 d before MCAO | NS | Ginsenoside, 12.5 mg/kg, qd,/, 3 d | mNSS |
Yang S 2016 (China) [43] | Rat/SD (M, 250–290 g) | MCAO/R | 6/6 | 2 h | 1 h before MCAO | NS | Sinomenine, 90 mg/kg,/, i.v., 1 d | mNSS, BWC |
Li WH 2020 (China) [6] | Rat/SD (M, 240–260 g) | MCAO/R | 3/3 | 1 h | NI | NS | Baicalein, 100 mg/kg,/, i.g., 7 d | BWC, IV |
Zheng XF 2023 (China) [44] | Mice/CD1 (M, 25–30 g) | MCAO/R | 10/10 | 1 h | 0 h after MCAO | NS | Salvianolic acid, 30 mg/kg,/, i.p., 3 d | BWC |
Zheng YQ 2018 (China) [45] | Rat/M/SD 220–230 g | MCAO/R | 12/12 | 1.5 h | 0.5 h before MACO | NS | Bilobalide, 10 mg/kg, qd, d.a., 7 d | IV |